RNAC Q4 2017 Earnings — Cartesian Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

RNACCartesian Therapeutics, Inc.

$216M

Q4 2017 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$17,000-99.4% YoY

Gross Profit

$17,000100.0% margin

Operating Income

-$19M-113394.1% margin

Net Income

-$20M-114964.7% margin

EPS (Diluted)

$-26.33

QoQ Revenue Growth

-37.0%

Cash Flow

Operating Cash Flow

-$13M

Free Cash Flow

-$13M

Stock-Based Comp.

$1M

Balance Sheet

Total Assets

$101M

Total Liabilities

$49M

Stockholders' Equity

$52M

Cash & Equivalents

$71M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$17,000	$3M	-99.4%
Gross Profit	$17,000	$3M	-99.4%
Operating Income	-$19M	-$14M	-39.1%
Net Income	-$20M	-$14M	-38.8%